{"entity":{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","aka":["HBI0101 CAR-T"],"tldr":"NXC-201 CAR-T is an experimental CAR-T cell therapy from Nexcella in phase 2 trials, aimed at BCMA.","summary":"NXC-201 CAR-T (NXC-201, HBI0101) is a CAR-T cell therapy developed by Nexcella. Its target is BCMA. The sponsor states: Autologous T cells transduced ex vivo with an anti-BCMA CAR retroviral vector, provided fresh without cryopreservation. ClinicalTrials.gov describes the intervention as: NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryop. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06097832, plans to enrol 45 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov. The published efficacy data come from the Hadassah phase 1 in relapsed or refractory multiple myeloma (NCT04720313; Haematologica 2023): overall response 75 percent and complete response 50 percent in the first 20 patients, with only grade 1 to 2 cytokine release syndrome.","status":"phase-2","asOf":"2026-09-24","links":[{"label":"HBI0101 phase 1 (Haematologica 2023)","url":"https://doi.org/10.3324/haematol.2022.281628"},{"label":"ClinicalTrials.gov NCT04720313","url":"https://clinicaltrials.gov/study/NCT04720313"},{"label":"ClinicalTrials.gov: trials of NXC-201 CAR-T","url":"https://clinicaltrials.gov/search?intr=NXC-201"},{"label":"Sponsor pipeline page","url":"https://www.nexcella.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":[],"companies":["immix-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nxc-201-mm"],"people":[],"bottlenecks":[],"keyPapers":["paper-nxc-201-hbi0101-asherie-haematologica-2023"],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"NXC-201, HBI0101","modality":"CAR-T cell therapy","mechanism":"Autologous T cells transduced ex vivo with an anti-BCMA CAR retroviral vector, provided fresh without cryopreservation.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/nxc-201-car-t/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"immix-biopharma","kind":"company","name":"Immix Biopharma","route":"/companies/immix-biopharma/"}],"trial":[{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/"}],"paper":[{"id":"paper-nxc-201-hbi0101-asherie-haematologica-2023","kind":"paper","name":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)","route":"/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/"}]}}